Remission of polycystic ovary syndrome associated with valproic acid in an epileptic female;Remisión de un síndrome de ovario poliquístico asociado a ácido valproico en una mujer epiléptica

Revista de Neurologia

Volumn 36, Issue 7, 2003, Pages 639-642

  Ribacoba Montero, R ^a   Martinez Faedo C ^a   Diaz Diaz C ^a   Salas Puig, J ^b  

^a Hospital Alvarez Buylla   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Epileptic female; Hyperandrogenism; Lamotrigine; Polycystic ovary syndrome (PCOS); Valproic acid

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; EPILEPSY; ETHNOLOGY; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; INCIDENCE; MENSTRUATION DISORDER; OBESITY; OVARY POLYCYSTIC DISEASE; REPRODUCTION; VIRILIZATION;

EID: 0038294365     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3607.2002476     Document Type: Article

References (18)

1. Fatterweit W. Polycystic ovary syndrome: clinical perspectives and management. Obstet Gynecol Surv 2000; 54: 403-15.
2. Herzog AG. A relationship between particular reproductive endocrine disorders and epileptiform discharges in women with epilepsy. Neurology 1993; 43: 1907-10.
3. Herzog A, Seibel M, Schomer DL, Vaitukaitis JL, Geswind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 341-6.
4. Isojärvi J. Laatikainer TJ, Pakarinen AJ, Juntunen K, Myllyla V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Eng J Med 1983; 329: 1383-8.
5. Murrialdo G, Galimberti CA, Gianelli MV, Rollero A, Pollero A, Copello F, et al. Menstrual cycle and ovary alteration in women with epilepsy on antiepileptic drugs. J Endocrinol Invest 1997; 20: 519-26.
6. Bauer J, Jarre A, Klingmüller D, Elger CE. Polycistic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000; 41: 163-7.
7. Isojarvi J, Tapanainen J. Valproate, hyperandrogenism and polycystic ovaries. Arch Neurol 2000; 57: 1064-6.
8. Rättyä J, Vainionpää L, Knip M, Lanning P, Isojärvi J. The effects of valproate, carbamazepine and oxcarbamazepine on growth and sexual maduration in girls with epilepsy. Pediatrics 1999; 103: 388-93.
9. Isojärvi J, Laatikainer TJ, Knip M, Pakarinen AJ, Kaisa TS, Juntunen K, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 30: 579-84.
10. Sozen H, Arici A. Hyperinsulinism and its interaction with hyperandrogenism in policystic ovary syndrome. Obstet Gynecol Surv 2000; 55: 321-8.
11. Dunaif A. Hyperandrogenic anovulation (POCS): a unique disorder of insulin action associated with increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: (Suppl 1 A): S33-9.
12. Poretsky L, Cataldo N, Rosenwaks Z, Giudice L. The insulin related ovarian regulatory system in health and disease. Endocr Rev 2000; 20: 535-82.
13. Murialdo G, Galimberti CA, Gianlelli MV, Rollero A, Polled A, Copello F, et al. Effects of valproate, phenobarbital and carbamazepine on sex steroid setup in women with epilepsy. J Clin Neuropharmacol 1998; 20: 52-8.
14. Stoffel-Wagner B, Bauer J, Flugel D, Brememan W, Klingmuller D, Elger CE. Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication. Epilepsia 1998; 39: 1164-73.
15. Popovic V, Spremovic S. The effect of sodium valproate on lutheinizing hormone secretion in women with polycistic ovary disease. J Endocrinol Invest 1995; 18: 104-8.
16. Rättya J, Pakarinen AJ, Knip M, Repo-Outakoski M, Myllylá VV, Isojärvi JIT. Early hormonal changes during valproate or carbamazepine treatment. A 3-month study. Neurology 2001; 57: 440-4.
17. Morrell MJ. Epilepsy in women: the science of why it is special. Neurology 1999; 53: (Suppl 1): S42-8.
18. Brunig JC, Gautan-Oburks DI, Orban PC, Kelin R, Krone W, Muller-Wirland D, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-5.